ESR1 and breast carcinoma: Among them, fulvestrant is the only selective estrogen receptor degrader approved for clinical use as a monotherapy for first- and second-line treatment in the context of estrogen receptor-positive advanced breast cancer (Blackburn et al., 2018; Soleja et al., 2019).